Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 2, 2015, Pages 294-301.e5

  Fukudo, Shin ^a   Hongo, Michio ^b   Kaneko, Hiroshi ^c   Takano, Masahiro ^d   Ueno, Ryuji ^e  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kurokawa Hospital   (Japan)

^c Hoshigaoka Maternity Hospital   (Japan)

^d TAKANO HOSPITAL   (Japan)

^e Sucampo AG   (Switzerland)

Author keywords

Functional Disorder; IBS; Intestine; QOL; Rome III Criteria; Small Bowel Transit

Indexed keywords

LUBIPROSTONE; GASTROINTESTINAL AGENT; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ARTICLE; CHRONIC IDIOPATHIC CONSTIPATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS BOWEL MOVEMENT; THORAX PAIN; VOMITING; AGED; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; INTESTINE; JAPAN; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINES; JAPAN; LUBIPROSTONE; MALE; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927613102     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.08.026     Document Type: Article

References (28)

1. Chang L., Toner B.B., Fukudo S., et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006, 130:1435-1446.
2. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
3. Bharucha A.E., Wald A., Enck P., et al. Functional anorectal disorders. Gastroenterology 2006, 130:1510-1518.
4. Watanabe T., Nakaya N., Kurashima K., et al. Constipation, laxative use and risk of colorectal cancer: the Miyagi Cohort Study. Eur J Cancer 2004, 40:2109-2115.
5. Cuppoletti J., Malinowska D.H., Tewari K.P., et al. SPI-0211 activates T84 cell chloride transport and recombinant human CIC-2chloride currents. Am J Physiol Cell Physiol 2004, 287:C1173-C1183.
6. Ueno R., Osama H., Habe T., et al. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology 2004, 126(Suppl 2):298.
7. Camilleri M., Bharucha A.E., Ueno R., et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006, 290:G942-G947.
8. Johanson J.F., Morton D., Geenen J., et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008, 103:170-177.
9. Barish C., Drossman D., Johanson J., et al. Efficacy and safety of lubiprostone in chronic constipation. Dig Dis Sci 2010, 55:1090-1097.
10. Schmulson M., Chang L. Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther 2011, 33:1071-1086.
11. Fukudo S., Hongo M., Kaneko H., et al. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011, 23. 544-e205.
12. Johanson J.F., Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007, 25:1351-1361.
13. Simrén M., Barbara G., Flint H.J., et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013, 62:159-176.
14. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214. Human Microbiome Project Consortium.
15. Drossman D.A., Chey W.D., Johanson J.F., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009, 29:329-341.
16. Ware J.E., Sherboume C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
17. Fukuhara S., Ware J.E., Kosinski M., et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. JClin Epidemiol 1998, 51:1045-1053.
18. Patrick D.L., Drossman D.A., Frederick I.O., et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998, 43:400-411.
19. Drossman D.A., Patrick D.L., Whitehead W.E., et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000, 95:999-1007.
20. Kanazawa M., Drossman D.A., Shinozaki M., et al. Translation andvalidation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med 2007, 1:6.
21. Whitehead W.E., Levy R.L., Von Korff M., et al. The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:1305-1315.
22. International conference on harmonisation; guidance on statistical principles for clinical trials; availability-FDA. Notice. Fed Regist 1998, 63:49583-49598.
23. Owen R.T. Lubiprostone-a novel treatment for irritable bowel syndrome with constipation. Drugs Today (Barc) 2008, 44:645-652.
24. Moeser A.J., Nighot P.K., Engelke K.J., et al. Recovery of mucosal barrier function in porcine ileum and colon is stimulated by a novel agonist of ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007, 292:G647-G656.
25. Creed F., Fernandes L., Guthrie E., et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124:303-317.
26. Chey W.D., Drossman D.A., Johanson J.F., et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012, 35:587-599.
27. Shepherd S.J., Gibson P.R. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. JAm Diet Assoc 2006, 106:1631-1639.
28. Okami Y., Kato T., Nin G., et al. Lifestyle and psychological factors related to irritable bowel syndrome in nursing and medical school students. JGastroenterol 2011, 46:1403-1410.